- The AccuVAC-D001 cancer vaccine demonstrated a 70 per cent cure rate of mice with pre-established solid tumours
- Non-specific degradation of endocytosed cancer antigens by endo-lysosomal organelles in dendritic cells (DCs) limits the effectiveness of cancer vaccinations
- The AccuVACTM protects endocytosed antigen from non-specific endosomal degradation
- The core of Defence Therapeutics’ platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens to target cells
- Defence Therapeutics Inc. is a biotechnology company
- Defence Therapeutics Inc. (DTC) opened trading at C$3.35 per share
Defence Therapeutics (DTC) is pleased to announce the completion of its AccuVAC-D001 cancer vaccine pre-clinical study.
The AccuVAC-D001 cancer vaccine demonstrated a 70 per cent cure rate of mice with pre-established solid tumours, confirming an effective anti-tumoral response.
Non-specific degradation of endocytosed cancer antigens by endo-lysosomal organelles in dendritic cells (DCs) is a major limitation in the field of cancer vaccination.
The AccuVACTM protects endocytosed antigen from non-specific endosomal degradation by promoting its escape via endosomal membrane disruption.
Endocytosed antigens accumulate – in their closest native state – in the cytosol of DC cells consequently resulting in efficient antigen cross-presentation to responding immune cells.
AccuVACTM dramatically improved protein processing and cross-presentation by ex vivo developed monocyte-derived DCs, which elicited potent CD4 and CD8 T-cell responses compared to the use of naked antigen.
The net outcome culminates into effective anti-tumoral responses curing 70 per cent of animals with pre-established solid tumours.
“The solid results of the AccuVACTM study demonstrates how this strategy can be positively adapted to engineered universal DC vaccines. This puts Defence and its technology on the path for future development of universal therapeutic vaccines for cancer and infectious diseases vaccines”, says Mr. Plouffe, CEO of Defence Therapeutics.
According to Future Business Insights, the market for vaccines is projected to reach US$104.87 billion by 2027.
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation of vaccines and ADC products using its proprietary platform.
The core of Defence Therapeutics’ platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Defence Therapeutics Inc. is a biotechnology company that researches and develops the effective delivery of tumor-/ and infectious disease-specific therapeutics.
Defence Therapeutics Inc. (DTC) opened trading at C$3.35 per share.